

Supplementary (online only) materials

Supplementary Table 1 Correlation analysis performed

Variables

Changes in DAS28 up to week 12 vs week 24

Changes in GLOESS (22 paired joints, reduced 9 paired joint set) from baseline up to week 12 vs baseline to week 24

Changes in GLOESS (MCPs 2–5, 22 paired joints, reduced 9 paired joint set) from baseline up to week 12 and lower levels of synovitis* at week 24

Changes in GLOESS at week 1 and changes in GLOESS during the entire treatment period (baseline to week 24)

Changes in DAS28 and changes in GLOESS (MCPs 2–5, 22 paired joints, reduced 9 paired joint set, 28 joints[†]) or component scores (SH, PD, JE) from baseline

GLOESS (MCPs 2–5) or component scores (SH, PD, JE) vs SJC

GLOESS (MCPs 2–5) or component scores (SH, PD, JE) vs TJC

GLOESS (MCPs 2–5) or component scores (SH, PD, JE) vs SJC + TJC combined

Changes in GLOESS (MCPs 2–5, 22 paired joints, reduced 9 paired joint set) week or components (SH, PD, JE) up to week 4 vs change in the sum of swollen joints (MCPs 2–5, 22 paired joints, reduced 9 paired joint set) at weeks 12 and 24

*Defined by a GLOESS at week 24 that was less than the median GLOESS at that time point. [†]The 28 joints assessed for tenderness and swelling as part of the DAS28. DAS28, Disease Activity Score 28; GLOESS, Global OMERACT-EULAR Synovitis Score; JE, joint effusion; MCPs, metacarpophalangeal joints; PD, power Doppler assessed synovial vascularization; SH, hypoechoic synovial hyperplasia; SJC, swollen joint count; TJC, tender joint count.

Supplementary Table 2 Correlation between changes in GLOESS up to week 12 and achieving lower levels of synovitis at week 24 (defined as having a GLOESS at week 24 that is less than the median value at that time point)

	Spearman's correlation coefficient		
	MCPs (2–5)	22 paired joint set	Reduced 9 paired joint set
Baseline to week 1	–0.36 (–0.53, –0.14)	–0.01 (–0.23, 0.21)	0.07 (–0.16, 0.30)
Baseline to week 2	–0.20 (–0.39, 0.02)	–0.02 (–0.23, 0.19)	–0.01 (–0.23, 0.20)
Baseline to week 4	–0.44 (–0.59, –0.24)	–0.19 (–0.39, 0.03)	–0.08 (–0.30, 0.14)
Baseline to week 8	–0.31 (–0.49, –0.10)	–0.15 (–0.36, 0.07)	0.09 (–0.14, 0.31)
Baseline to week 12	–0.55 (–0.68, –0.37)	–0.30 (–0.49, –0.09)	–0.16 (–0.37, 0.06)

CI, confidence interval; GLOESS, Global OMERACT-EULAR Synovitis Score; MCPs, metacarpophalangeal joints.

Supplementary Table 3 Standardized response means for changes in DAS28 and GLOESS using the MCP 2–5, 22 paired, and reduced 9 paired joint sets

Measure	Time point	n	Mean change from baseline	SE	SD	SRM*
DAS28	Week 1	91	−0.55	0.078	0.743	−0.734
	Week12	103	−1.77	0.113	1.149	−1.542
	Week 24	103	−2.13	0.136	1.379	−1.541
GLOESS (MCPs 2–5)	Week 1	86	−0.70	0.282	2.615	−0.268
	Week12	95	−3.80	0.454	4.425	−0.859
	Week 24	95	−4.80	0.473	4.610	−1.041
GLOESS (22 paired joints)	Week 1	87	−1.70	0.852	7.947	−0.214
	Week12	95	−11.70	1.39	13.548	−0.864
	Week 24	95	−15.70	1.65	16.082	−0.976
GLOESS (reduced 9 paired joint set)	Week 1	81	−0.60	0.362	3.258	−0.184
	Week12	91	−5.30	0.583	5.561	−0.953
	Week 24	91	−6.40	0.725	6.916	−0.925

*SRM was calculated by dividing the mean change from baseline by the SD of the change. DAS28, Disease Activity Score 28; GLOESS, Global OMERACT-EULAR Synovitis Score; MCP, metacarpophalangeal; SD, standard deviation; SE, standard error; SRM, standardized response mean.